Soleno Therapeutics (NASDAQ:SLNO) issued its earnings results on Tuesday. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.12), Bloomberg Earnings reports.
Shares of Soleno Therapeutics stock traded down $0.16 on Wednesday, hitting $2.50. The stock had a trading volume of 763 shares, compared to its average volume of 118,088. Soleno Therapeutics has a one year low of $1.32 and a one year high of $3.70. The stock has a market capitalization of $53.38 million, a price-to-earnings ratio of -1.81 and a beta of 5.10.
Several research analysts have recently issued reports on SLNO shares. ValuEngine upgraded shares of Soleno Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Noble Financial set a $4.00 target price on shares of Soleno Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 16th. Maxim Group set a $4.00 target price on shares of Soleno Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 16th. Finally, Roth Capital started coverage on shares of Soleno Therapeutics in a report on Friday, June 22nd. They issued a “buy” rating and a $14.00 target price on the stock. Five analysts have rated the stock with a buy rating, Soleno Therapeutics presently has a consensus rating of “Buy” and an average target price of $7.50.
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, diazoxide choline controlled-release (DCCR), a tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into late-stage clinical development.
Recommended Story: What are CEFs?
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.